Levi & Korsinsky notifies investors that it has commenced an investigation into Biohaven Ltd. (NYSE: BHVN) concerning potential violations of the federal securities laws.
Biohaven issued a press release on May 14, 2025, “announc[ing] that the Division of Neurology 1 within FDA’s Office of Neuroscience informed the Company that they are extending the PDUFA date for the troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the FDA.” The press release further stated that “[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.”
Following this news, Biohaven’s stock price fell over 19% on May 15, 2025.
If you suffered a loss on your Biohaven Ltd. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





